Lv4
426 积分 2024-03-26 加入
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
2个月前
已完结
Rethinking ovarian cancer III: the past decade and future directions
2个月前
已完结
Double-strand break repair: 53BP1 comes into focus
2个月前
已完结
Correction: Corrigendum: Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
2个月前
已完结
Targeting Poly (ADP-ribose) polymerase-1 (PARP-1) for DNA repair mechanism through QSAR-based virtual screening and MD simulation
2个月前
已完结
RGS5+ lymphatic endothelial cells facilitate metastasis and acquired drug resistance of breast cancer through oxidative stress-sensing mechanism
2个月前
已完结
Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer
2个月前
已完结
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
2个月前
已完结
Global epidemiology of epithelial ovarian cancer
2个月前
已完结
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
